Journal ArticleDOI
The 2001 Bethesda System: terminology for reporting results of cervical cytology.
Diane Solomon,Diane D. Davey,Robert J. Kurman,Marianne U. Prey,Stephen S. Raab,Mark E. Sherman,David C. Wilbur,Nancy A. Young +7 more
TLDR
The 2001 Bethesda System terminology reflects important advances in biological understanding of cervical neoplasia and cervical screening technology.Abstract:
ObjectivesThe Bethesda 2001 Workshop was convened to evaluate and update the 1991
Bethesda System terminology for reporting the results of cervical cytology.
A primary objective was to develop a new approach to broaden participation
in the consensus process.ParticipantsForum groups composed of 6 to 10 individuals were responsible for developing
recommendations for discussion at the workshop. Each forum group included
at least 1 cytopathologist, cytotechnologist, clinician, and international
representative to ensure a broad range of views and interests. More than 400
cytopathologists, cytotechnologists, histopathologists, family practitioners,
gynecologists, public health physicians, epidemiologists, patient advocates,
and attorneys participated in the workshop, which was convened by the National
Cancer Institute and cosponsored by 44 professional societies. More than 20
countries were represented.EvidenceLiterature review, expert opinion, and input from an Internet bulletin
board were all considered in developing recommendations. The strength of evidence
of the scientific data was considered of paramount importance.Consensus ProcessBethesda 2001 was a year-long iterative review process. An Internet
bulletin board was used for discussion of issues and drafts of recommendations.
More than 1000 comments were posted to the bulletin board over the course
of 6 months. The Bethesda Workshop, held April 30-May 2, 2001, was open to
the public. Postworkshop recommendations were posted on the bulletin board
for a last round of critical review prior to finalizing the terminology.ConclusionsBethesda 2001 was developed with broad participation in the consensus
process. The 2001 Bethesda System terminology reflects important advances
in biological understanding of cervical neoplasia and cervical screening technology.read more
Citations
More filters
Journal ArticleDOI
Molecular epidemiology and genotype distribution of Human Papillomavirus (HPV) among Arab women in the State of Qatar.
Devendra Bansal,Asha Elmi,Sini Skariah,Pascale Haddad,Laith J. Abu-Raddad,Aysha H Al Hamadi,Nady Mohamed-Nady,Nahla M Affifi,Randa Ghedira,Elham Hassen,Asma Althani,Afaf A H M Al-Ansari,Ali A. Sultan +12 more
TL;DR: The overall HPV prevalence in Arab women in Qatar was identified as 6.1% with an increased HPV prevalence seen in women with abnormal cytology results and no significant trends seen with age.
Journal ArticleDOI
Immunocytochemical staining of p16INK4a protein from conventional Pap test and its association with human papillomavirus infection
Chamsai Pientong,Tipaya Ekalaksananan,Bunkerd Kongyingyoes,Onanong Kritpetcharat,Ussanee Swadpanich,Prasit Pengsa,Pissamai Yuenyao +6 more
TL;DR: It is suggested that immunocytochemical staining of p16INK4a on CPT slides is convenient and cost‐effective for cervical cancer screening by the detection of dysplastic cells infected with HR‐HPV.
Journal ArticleDOI
Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years.
TL;DR: The prophylactic quadrivalent HPV vaccine could significantly reduce the acquisition of infection and clinical disease caused by HPV types 6, 11, 16 and 18 and was well tolerated in Japanese women aged 18–26 years.
Journal ArticleDOI
Canadian oncogenic human papillomavirus cervical infection prevalence: Systematic review and meta-analysis
TL;DR: The results support vaccinating females < 20 years of age, along with targeted vaccination of some groups (e.g., under-screened populations), and poor study quality and heterogeneity suggests that high-quality studies are needed.
Journal ArticleDOI
Carcinogenesis Associated with Human Papillomavirus Infection. Mechanisms and Potential for Immunotherapy
M S Vonsky,M. Shabaeva,A L Runov,N. Lebedeva,S. Chowdhury,Joel M. Palefsky,Maria G. Isaguliants +6 more
TL;DR: The vaccine elicits immune response that prevents initial infection with a given HPV type but does not eliminate persistent virus once infection has occurred and does not prevent development of the HPV-associated neoplasias, which necessitates the development of therapeutic vaccines to treat chronic HPV infections and HPV- associated malignancies.
References
More filters
Journal ArticleDOI
Natural history of cervicovaginal papillomavirus infection in young women
TL;DR: An increased risk of HPV infection was significantly associated with younger age, Hispanic ethnicity, black race, an increased number of vaginal-sex partners, high frequencies of vaginal sex and alcohol consumption, anal sex, and certain characteristics of partners.
Journal ArticleDOI
Natural History of Cervicovaginal Papillomavirus Infection in Young Women Gyf Ho
TL;DR: The incidence of HPV infection in sexually active young college women is high and the short duration of most HPV infections in these women suggests that the associated cervical dysplasia should be managed conservatively.
Journal ArticleDOI
Papillomaviruses Causing Cancer: Evasion From Host-Cell Control in Early Events in Carcinogenesis
TL;DR: Modifications in host-cell genes, most likely engaged in the control of HPV gene expression in proliferating cells, emerge as important events in HPV-mediated carcinogenesis.
Journal ArticleDOI
2001 Consensus Guidelines for the Management of Women With Cervical Cytological Abnormalities
TL;DR: Management of women with atypical squamous cells (ASC) depends on whether the Papanicolaou test is subcategorized as of undetermined significance (ASC-US) or as cannot exclude high-grade squamous intraepithelial lesion (HSIL) (asc-H).
Journal ArticleDOI
Comparison of Three Management Strategies for Patients With Atypical Squamous Cells of Undetermined Significance: Baseline Results From a Randomized Trial
TL;DR: HC 2 testing for cancer-associated HPV DNA is a viable option in the management of women with ASCUS and has greater sensitivity to detect CIN3 or above and specificity comparable to a single additional cytologic test indicating ASCUS or above.